中西医结合治疗胃癌前期病变单抗MG9阳性40例临床分析

胃粘膜异型增生，已公认为一种胃癌前期病变，具有癌变的潜在趋向，如同时胃癌单克隆抗体MG9阳性则癌变的危险性就更高，因此，半有异型增生单抗MG9阳性病例的治疗更为棘手，近几年来，作者应用中西医结合的方法，收到较好疗效。     

中西医结合治疗慢性萎缩性胃炎胃癌前期病变48例

自 1 995年 6月～ 2 0 0 0年 1 2月 ,我们运用中西医结合方法治疗慢性萎缩性胃炎 ( CAG)胃癌前期病变 48例 ,疗效满意 ,现报告如下。1　资料与方法1 .1　临床资料 :85例均为本院消化门诊或住院患者 ,均经胃镜、病理检查确诊为 CAG,且伴肠上皮化生 ( IM)或不典型增生 ( ATP) ,幽门螺杆菌 ( Hp)检查采用快速尿素酶实验及胃窦粘膜组织培养。随机分为治疗组 48例 ,其中男 2 9例 ,女 1 9例 ;年龄 2 3～ 68岁 ,平均 41 .2岁 ;病程 1 1个月～ 2 6年 ,平均 5 .7年 ;伴 IM者 2 7例 ,ATP者 2 1例 ;Hp者阳性 35例。对照组 37例 ,其中男 2 4例 ,…     

中西医结合治疗癫痫40例临床观察

癫痫是一种古老而顽固的疾病 ,给患者及其家庭带来极大的精神痛苦和经济负担 ,其中尤以癫痫大发作 ,不仅发病率高 ,而且对患者身心损害最为严重。在我国早于 2 0 0 0多年前成书的《黄帝内经》中即有有关癫痫的描述 ,历代医家见仁见智 ,传世许多治疗方法及方药 ,确有一定效验。近代迅速发展的西医学以其更加严谨科学的理论、治疗方法及诸多药物使癫痫的治疗有了很大改观 ,但由于癫痫的顽固复杂性等等原因 ,临床治疗失败者仍屡见不鲜。为进一步验证中药治疗癫痫的确切疗效 ,同时为拓展治疗思路及探寻新的治疗方法 ,笔者采用中药或中药为主加用…     

中药治疗胃癌前期病变的临床观察

对１２年来２００余例经病理检查产的慢性萎缩性胃炎（ＣＡＧ）患者，根据不同临床分型，以温中和胃为基本大法，配合活血化瘀、清热解药并经物治疗，经过３年反复临床验证，取得良好效果。从资料完整的８０例病例与治疗前比较，其临床疗效；显效４７例，有效２４例，无效９例，有效率８８．７％。胃镜检查；显效４２例，有效２４例，无产１４例，有效率８２．５％，病理组织检查；显效２１例，有效３４例，无效２３例，癌变２例，有     

中药治疗胃癌前期病变的临床观察

对12年来200余例经病理检查证实的慢性萎缩性胃炎（CAG）患者，根据不同临床分型，以温中和胃为基本大法，配合活血化瘀、清热解毒药物治疗，经过3年反复临床验证，取得良好效果。从资料完整的80例病例与治疗前比较，其临床疗效：显效47例，有效24例，无效9例，有效率88．7％。胃镜检查：显效42例，有效24例，无效14例，有效率82．5％。病理组织检查：显效21例．有效34例，无效23例，癌变2例，有效率68．7％。同时可降低血粘稠度，使胃酸分泌增高。     

中医药辨证治疗胃癌前期病变临床观察

中医药辨证治疗胃癌前期病变临床观察张子理慢性萎缩性胃炎（ＣＡＧ）是常见而难治的消化道疾病。作者近年来采用中医药辨证施治结合活血化瘀、解毒抗癌、微观加药的方法治疗了ＣＡＧ合并中度以上异型增生（ＤＳ）或肠上皮化生（ＩＭ）的胃癌前期病变（ＰＣＬ）患者６８例...     

中西医结合治疗病毒性心肌炎40例分析

将78例病毒性心肌炎患者随机分为治疗组40例与对照组38例,对照组给予常规西药治疗,治疗组在常规西药治疗的基础上加用自拟益气解毒汤,结果治疗组的总有效率为90.00%,对照组为73.68%（P＜0.05）.认为中西医结合治疗病毒性心肌炎比单用西药治疗疗效好.     

中西医结合治疗急性胆源性胰腺炎40例临床分析

采用中西医结合方法治疗急性胆源性胰腺炎４０例，结果表明，４０例中痊愈２６例，显效１２例，有效率达９５％。提示，中医的“通里攻下，清热解毒、活血化淤”三个法则结合西药是治疗该病的有效方法。     

养胃防癌方治疗胃癌前期病变的临床研究

根据胃癌前期病变的临床特点，采用益气活血清热方法，研制成养胃防癌方，临床采用随机对照的方法治疗胃癌前期病变170例。结果治疗组临床有效率90．0％，明显优于对照组（P＜005），并对中药的作用机制进行了探讨。     

残胃癌25例诊治分析

目的:探讨残胃癌发生的可能因素及早期诊断。方法:对本院10年来25例残胃癌的临床资料进行回顾性分析。结果:B-Ⅱ式手术残胃癌的发生率比B-I式高出 5.22倍.与术后经过时间呈正相关。本组残胃癌发生时间平均为手术后15.1年。结论:择期手术尽量推迟至45岁以上。尽量避免行B-Ⅱ式手术。加强胃术后患者随访。     

复方菥蓂治疗甲胎蛋白阳性肝病54例初步观察

采用复方菥蓂治疗54例甲胎蛋白(AFP)阳性肝病患者。对 AFP 阳性原发性肝癌,AFP 下降率为71.34％,明显高于对照组的22.22％(P<0.01);半年以上生存率为66.67％,明显高于对照组的27.78％(P<0.01);对 AFP 低持阳肝病,AFP 阴转率为93.94％,明显高于对照组的66.67％(P<0.05);随访1～3年,肝癌发生率为3.03％,明显低于对照组的22.22％(P<0.05)。初步认为,本方是阻遏 AFP 阳性的有效药物。     

2型糖尿病胃轻瘫脾胃亏虚证患者实施中药治疗的效果分析

目的分析2型糖尿病胃轻瘫脾胃亏虚证实施中药治疗的临床疗效。方法研究对象选择该院2018年1—12月收治的68例2型糖尿病胃轻瘫脾胃亏虚证患者,将其划分为观察组和对照组,每组34例。对照组选择常规基础治疗结合莫沙必利片口服治疗,观察组则采用基础治疗配合中药汤剂治疗。比较两组患者治疗后的临床症状改善情况来判定疗效。结果该次研究结果表明,观察组的临床疗效达到了94.1%,而对照组的临床疗效只有79.4%,数据差异有统计学意义(P<0.05)。结论2型糖尿病胃轻瘫脾胃亏虚证患者实施中药治疗能够保障患者胃动力恢复正常,且在不影响血糖水平的前提下有效改善临床症状。     

An Integrated Alcohol Abuse and Medical Treatment Model for Patients with Hepatitis C

Background  

Patients with chronic hepatitis C virus (HCV) infection have high rates of alcohol consumption, which is associated with progression of fibrosis and lower response rates to HCV treatment.     

超滤浓缩回输治疗顽固性腹水40例

目的:探讨腹水超滤浓缩回输治疗顽固性腹水的疗效及其影响因素。方法:采用FCN—01型腹水超滤浓缩回输机及DY—1060一次性型腹水浓缩器对40例顽固性腹水患者在抽取腹水浓缩后根据情况进行静脉或腹腔内回输。结果:40例患者平均每次抽水5246±1147ml。腹水浓缩7.32±3.36倍,平均减少腹围10.3±4.5cm,平均每次回输蛋白量85.3±74.6g。回输后尿量平均增加602.4±112.3ml/24h。40例中显效20例(50%),有效14例(35％),无效6例(15％),总有效率85％。结论:超滤浓缩回输既有消除腹水又有节省蛋白的双重效果,是临床上治疗顽固性腹水的一种有效方法。     

Early Cancer of the Stomach Arising after Successful Treatment of Gastric MALT Lymphoma in Patients with Autoimmune Disease

Background: Extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) arises in lymphoid tissue acquired through chronic antigenic stimulation as exemplified by Helicobacter pylori. Secondary development of gastric cancer, however, is thought to be a rare event. The detection of a signet ring cell carcinoma during follow-up endoscopy after successful therapy of MALT lymphoma in a patient with Sjogren's syndrome prompted us to analyse the frequency of subsequent gastric cancer in patients with underlying autoimmune disease (AD). Methods: Patients with early stage MALT lymphoma and an underlying AD were evaluated for the occurrence of a secondary gastric cancer during the course of follow-up. Data analysed included the type of AD, stage of MALT lymphoma, H. pylori status, treatment for MALT lymphoma and response, follow-up, the presence of a secondary cancer, and time to development of cancer. In all patients, histologic samples were reassessed for the extent of gastritis, presence of intestinal metaplasia or focal atrophy at the time of lymphoma diagnosis. Results: A total of eight patients with overt AD at the time of diagnosis of MALT lymphoma were identified. All patients were women aged between 56 and 77 years; 5 had Sjogren's syndrome, 2 had autoimmune thyroiditis (1 along with psoriasis) and 1 suffered from polymyalgia rheumatica. All patients had early stage MALT lymphoma restricted to the mucosa and submucosa at the time of diagnosis, and the presence of H. pylori was found in all cases. Two of these patients achieved complete remission (CR) of the lymphoma following H. pylori eradication, while six were judged unresponsive and underwent chemotherapy, resulting in CR in all cases. One patient died from stroke while being in CR for 2 months following chemotherapy. Two patients (25%) developed early cancer limited to the gastric mucosa while being in CR from lymphoma for 9 and 27 months, respectively, and underwent partial gastrectomy. Final staging of gastric cancer revealed pTlpNOMO in both cases. Of the remaining 5 cases, 1 patient had a local lymphoma relapse 18 months after CR and was salvaged with radiotherapy. In the remaining 4 patients, no evidence of lymphoma recurrence or a second malignancy has been found so far by regular follow-up every 3 months for a time-span between 52 and 63 months after initial diagnosis. Conclusion: Patients with concurrent MALT lymphoma and an underlying autoimmune condition show not only an impaired response to H. pylori eradication but might also be at increased risk for the development of gastric cancer. In view of this, such patients should be followed closely by regular endoscopies after remission of MALT lymphoma.     

Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant

There is a growing interest in using monoclonal antibodies (mAbs) in the early stages of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection to prevent disease progression. Little is known about the efficacy of mAbs against the delta variant of concern and its clinical presentations. We evaluated the effect of casirivimab/imdevimab treatment among five delta vaccine breakthrough patients. Symptomatic non-hospitalized vaccinated patients were submitted to nasopharyngeal swabs for the detection of SARS-CoV-2 and Next-Generation Sequencing (NGS). Blood analysis and chest Computed Tomography were also performed. A cocktail of casirivimab/imdevimab was administrated, and patients were monitored weekly. Clinical evolution was evaluated by the regression of the symptoms, negative results by real-time RT-PCR, and by the need of hospitalization: these aspects were considered as significant outcomes. In four cases, symptom reversion and viral load reduction were observed within 2 days and 7 days after mAbs treatment, respectively. Only one case, suffering from thymoma, was hospitalized 2 days later because of respiratory failure, which reverted within 18 days. mAbs treatment seems to be safe and effective against the delta variant and its clinical manifestations.     

慢性胃炎肝胃不和证本质的探讨(附150例报告)

为探讨慢性胃炎肝胃不和证的本质，以食道胃内压、胃肠激素、血环核苷酸、幽门螺杆菌、胃粘膜血流量及温度等项目为观察指标，结果发现肝胃不和组食管下括约肌静息压、屏障压、胃体压、胃窦压均明显低于正常对照组；幽门括约肌压力则明显低于正常对照组及脾胃虚弱组。血清胃泌素水平高于正常对照组，血浆胃动素浓度高于正常对照组和脾胃虚弱组，血浆胰高糖素水平高于正常对照组、低于脾胃虚弱组。血浆cAMP明显增高，cAMP／cGMP比值较正常及脾胃虚弱组增高。HP感染阳性率及胃粘膜活动性炎症检出率明显高于脾胃虚弱组。胃内各部位粘膜血流量及表面温度较正常对照组轻度减少，但无显著性差异。表明慢性胃炎肝胃不和证存在着胃、食道运动功能障碍、胃肠激素分泌异常及植物神经功能紊乱。